Glottis carcinoma
diseaseOn this page
Also known as cancer of glottiscancer of the glottiscarcinoma of glottiscarcinoma of the glottisglottic carcinomaglottic throat cancerglottis cancer
Summary
Glottis carcinoma (MONDO:0002355) is a cancer and 7 clinical trials. Top therapeutic interventions include mitomycin and curcumin. A subtype of glottis cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | glottis carcinoma |
| Mondo ID | MONDO:0002355 |
| DOID | DOID:2599 |
| NCIT | C4923 |
| SNOMED CT | 372103002 |
| UMLS | C0740083 |
| MedGen | 152820 |
| GARD | 0027605 |
| Anatomy (UBERON) | UBERON:0002486 |
| Is cancer (heuristic) | yes |
Also known as: cancer of glottis · cancer of the glottis · carcinoma of glottis · carcinoma of the glottis · glottic carcinoma · glottic throat cancer · glottis cancer · glottis carcinoma
Disease family
This is a subtype of glottis cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › larynx cancer › glottis cancer › glottis carcinoma
Subtypes (2): glottis squamous cell carcinoma, carcinoma of the vocal tract
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05688488 | PHASE1/PHASE2 | RECRUITING | Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords |
| NCT04908696 | Not specified | RECRUITING | Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) |
| NCT07391345 | Not specified | RECRUITING | Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer |
| NCT02184403 | Not specified | UNKNOWN | Quality of Life After Laser Cordectomy in Early Glottic Cancer |
| NCT03548285 | Not specified | COMPLETED | Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer |
| NCT04447456 | Not specified | COMPLETED | Comparison of Voice Results at 5 Years of Treatment of Glottic Squamous Cell Carcinoma T1 by Surgery Versus Radiotherapy |
| NCT05679856 | Not specified | UNKNOWN | Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MITOMYCIN | 4 | 1 |
| CURCUMIN | 3 | 1 |